A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)

Inclusion Criteria:

• Diagnosis of RA for ≥ 3 months who also fulfill the 2010 American College ofRheumatology (ACR)/ European League Against Rheumatism (EULAR) classification criteriafor RA.
• Participants have been receiving csDMARD therapy ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug.

1. Participants must have failed (lack of efficacy) at least one of the following:methotrexate (MTX), sulfasalazine, or leflunomide.
2. The following csDMARDs are allowed: oral or parenteral MTX, sulfasalazine,hydroxychloroquine, chloroquine, and leflunomide.
3. A combination of up to two background csDMARDs is allowed except the combinationof MTX and leflunomide.

• Participant meets both of the following disease activity criteria:

1. ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68joint counts) at Screening and Baseline Visits; and
2. High-sensitivity C-Reactive Protein (hsCRP) ≥ 3 mg/L at Screening

• Participants with prior exposure to at most one biological disease-modifyinganti-rheumatic drugs (bDMARD) may be enrolled (up to 20% of total number of subjects).Specifically, prior to enrollment:

1. Participants with limited exposure to bDMARD (< 3 months) OR
2. Participants who are responding to a bDMARD therapy but had to discontinue due tointolerability (regardless of treatment duration).

• Participants must have discontinued bDMARD therapy prior to the first dose of studydrug.

Exclusion Criteria:

• Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited totofacitinib, baricitinib, and filgotinib).
• Participants who are considered inadequate responders (lack of efficacy) to bDMARDtherapy as defined by the Investigator.
• History of any arthritis with onset prior to age 17 years or current diagnosis ofinflammatory joint disease other than RA (including but not limited to gout, systemiclupus erythematosus, psoriatic arthritis, axial spondyloarthritis including ankylosingspondylitis and non-radiographic axial spondyloarthritis, reactive arthritis, overlapconnective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia [currently with active symptoms]. Current diagnosis of secondary Sjogren's Syndrome ispermitted.